| Value | ₹8,869 Cr |
|---|
NSE filing, NSE: PPLPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Piramal Pharma Ltd: key numbers
- Share price
- ₹232.80
- Market cap
- ₹30,994 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -148.4×Sector 46.1×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Results Update
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Q2 FY27 Results: Turns Profitable, Net Profit ₹5 Cr
Piramal Pharma Ltd reported revenue from operations of ₹2,617 Cr (+28.1% YoY) and net profit of ₹5 Cr for Q2 FY27.
- Key figure
- Net profit ₹5 Cr
Piramal Pharma Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026. The report details equity distribution among promoters and public shareholders.
Piramal Pharma Board Meeting Date
Piramal Pharma Limited has scheduled a board meeting on October 27, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Piramal Pharma Adverse Business Impact
Piramal Pharma announced that its sales and distribution arrangement with Bayer Pharmaceuticals will expire on December 31, 2026, and will not be renewed.
- From
- Bayer Pharmaceuticals Private Limited
Other results update announcements
All →Zensar Technologies Results Update
Zensar Technologies reported 4.1% sequential constant currency revenue growth to $166.2M for Q2FY27, with EBITDA margin at 15.8%. The release is a press release accompanying the quarterly results presentation.
Dodla Dairy Results Update
Dodla Dairy's press release shows Q2 FY27 revenue up 17.4% but PAT down 44.3%. It also flags a proposed 40% stake in a joint venture with MIHL.
Fabtech Technologies Results Update
Fabtech released Q2 FY27 consolidated highlights, with revenue and profit down year-on-year. Management expects H2 execution to step up and targets an 8–9% PAT margin.
Creative Newtech Results Update
Creative Newtech reported Q2 FY27 standalone total income of Rs.664.55 Crore, with PAT up 78.43% YoY to Rs.12.65 Crore. The media release also covers consolidated results and recent acquisition and partnership developments.
ACME Solar Holdings Results Update
ACME Solar reported Q2 FY27 consolidated EBITDA of INR 874 Cr and PAT of INR 269 Cr. Both rose sharply year-on-year on BESS and RE capacity additions.
IIFL Capital Services Results Update
IIFL Capital Services reported consolidated Q2FY27 revenue of ₹722 crore, up 22% year-on-year, with PBT of ₹174 crore. The press release also covers the Fairfax change-in-control and a proposed NBFC subsidiary.